Relatlimab - A BMY emerging pipeline being tested with Opdivo + Halozyme's enhanze platform | BMY Message Board Posts

Bristol-Myers Squibb Co.

  BMY website

  •  Registered Members of Investor Village:
    Please make sure you are signed in to your Investor Village account to enjoy the full benefits of our service and avoid the MediaPass paywall. If the MediaPass offer page is blocking you, click the light blue "No thanks, take me back" link on the middle right side of the form to get to our home page where you can sign in by entering your Investor Village User Name and Password. 

     MediaPass subscribers: Please make sure you are logged in to your MediaPass subscription to bypass the paywall. You can do this by clicking the light blue "Already have a MediaPass account? Login here" link on the middle left side of the subscription offer form and then entering the email address and password you used when you first signed up with MediaPass.  

    For assistance call 888-222-7309 or email

BMY   /  Message Board  /  Read Message



Rec'd By
Authored By
Minimum Recs
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  763 of 3350  at  10/23/2019 2:10:03 AM  by


Relatlimab - A BMY emerging pipeline being tested with Opdivo + Halozyme's enhanze platform


Relatlimab (previously known as BMS-986016) is a cancer immunotherapy being developed by Bristol-Myers Squibb (BMS). The treatment has already shown benefit in melanoma patients and is also being tested in other cancers.

Immunotherapies use the body’s own immune system to fight cancer, instead of directly attacking cancer cells.

How relatlimab works

Relatlimab is an anti-LAG-3 antibody, which means that it binds to and inhibits LAG-3, a protein present on the surface of specialized immune cells called T-cells.

LAG-3 is an immune checkpoint protein whose job is to control the response, activation, and growth of T-cells that fight cancer cells, ensuring that the immune system does not attack healthy cells.

Some tumor cells have found a way to use these checkpoints for their own benefit, applying a brake on T-cells to avoid being detected and attacked.

When relatlimab binds to LAG-3 on T-cells, this process essentially releases those brakes, and stimulates T-cells to attack cancer cells. This way, the immune system is again able to work as intended against cancer, reducing tumor growth.

Relatlimab in clinical trials

Relatlimab is being investigated, alone and in combination with other treatments, in several types of cancer.

A Phase 1/2 study (NCT01968109) is investigating the safety, tolerability, and effectiveness of relatlimab with and without Opdivo (nivolumab), another immunotherapy produced by BMS, to treat various solid tumors.

Initial results from this study in patients with advanced melanoma, a type of skin cancer, were presented at the 2017 meeting of the American Society of Clinical Oncology (ASCO) and at the European Society for Medical Oncology (ESMO) 2017 Congress.

They showed, in 68 melanoma patients who did not respond to or became resistant to other immunotherapies, that the combination of relatlimab and Opdivo was well-tolerated and effective. Overall, 11.5 percent of patients responded to treatment. One achieved a complete response, six had partial responses, and 23 others had stable disease. Responses were 3.5 fold more likely in patients who were producing LAG-3.

However, the side effects of this combined treatment resulted in 10 percent of patients dropping out of the study.

The study is still recruiting in the U.S., Australia, Europe, Canada, Japan, and the U.K. to further evaluate the combination treatment in patients with melanoma and other solid tumors.

Other studies of relatlimab are ongoing and also recruiting participants.

A Phase 1/2 study (NCT02061761) that started in February 2014 is investigating the safety of relatlimab in hematologic cancers, which form in the blood or immune system. This study is currently recruiting in the U.S. and Canada.

Another Phase 1 study (NCT02658981) that started in August 2016 is recruiting in the U.S. to evaluate relatlimab alone or in combination with Opdivo in patients with glioblastoma, a type of cancer of the nervous system.

Phase 2 studies are also ongoing to test relatlimab in patients with cancers of the kidneys (NCT02996110), stomach (NCT02935634), lungs (NCT02750514), and colon (NCT02060188).



     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 4     Views: 220
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 All rights reserved. User Agreement
Financial Market Data provided by